Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yiling Lu

Showing results (161-170 of 224) with videos related to

Pageof 23
Sort By:
Nature Communications|October 30, 2022
Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targetsMasashi Fujita, Mei-Ju May Chen, Doris Rieko Siwak, et al.
Molecular & Cellular Proteomics : MCP|October 26, 2024
Targeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival BenefitKohei Kume, Midori Iida, Takeshi Iwaya, et al.
Cancer Treatment and Research|January 5, 2002
Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancerGordon B Mills, Astrid Eder, Xianjun Fang, et al.
Cancer Cell|March 14, 2018
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination DeficiencyChaoyang Sun, Jun Yin, Yong Fang, et al.
Oncogene|July 25, 2021
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanomaBeike Wang, Wei Zhang, Gao Zhang, et al.
Oncotarget|March 2, 2018
Distinct histone modifications denote early stress-induced drug tolerance in cancerAbdullah Al Emran, Diego M Marzese, Dinoop Ravindran Menon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 22, 2020
Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant MelanomaCharles Marusak, Varsha Thakur, Yuan Li, et al.
Cancer Biology & Therapy|April 28, 2009
Dual targeting of EphA2 and FAK in ovarian carcinomaMian M K Shahzad, Chunhua Lu, Jeong-Won Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2012
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivoFiona Simpkins, Pedro Hevia-Paez, Jun Sun, et al.
JCI Insight|January 19, 2017
A patient-derived-xenograft platform to study BRCA-deficient ovarian cancersErin George, Hyoung Kim, Clemens Krepler, et al.
Pageof 23

Showing results (161-170 of 224) with videos related to

Sort By:
Pageof 23
Nature Communications|October 30, 2022
Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targetsMasashi Fujita, Mei-Ju May Chen, Doris Rieko Siwak, et al.
Molecular & Cellular Proteomics : MCP|October 26, 2024
Targeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival BenefitKohei Kume, Midori Iida, Takeshi Iwaya, et al.
Cancer Treatment and Research|January 5, 2002
Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancerGordon B Mills, Astrid Eder, Xianjun Fang, et al.
Cancer Cell|March 14, 2018
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination DeficiencyChaoyang Sun, Jun Yin, Yong Fang, et al.
Oncogene|July 25, 2021
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanomaBeike Wang, Wei Zhang, Gao Zhang, et al.
Oncotarget|March 2, 2018
Distinct histone modifications denote early stress-induced drug tolerance in cancerAbdullah Al Emran, Diego M Marzese, Dinoop Ravindran Menon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 22, 2020
Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant MelanomaCharles Marusak, Varsha Thakur, Yuan Li, et al.
Cancer Biology & Therapy|April 28, 2009
Dual targeting of EphA2 and FAK in ovarian carcinomaMian M K Shahzad, Chunhua Lu, Jeong-Won Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2012
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivoFiona Simpkins, Pedro Hevia-Paez, Jun Sun, et al.
JCI Insight|January 19, 2017
A patient-derived-xenograft platform to study BRCA-deficient ovarian cancersErin George, Hyoung Kim, Clemens Krepler, et al.
Pageof 23